Voices
Ariella Hanker: AACR26 Is “Still” the Year of RAS Inhibitors
Ariella Hanker / LinkedIn

Ariella Hanker: AACR26 Is “Still” the Year of RAS Inhibitors

Ariella Hanker, Associate Professor at UT Southwestern Medical Center, shared a post on LinkedIn:

So, AACR26 is *still* the year of RAS inhibitors.

On that note, don’t miss Dr. Priya Hibshman’s late breaking poster (Monday afternoon) on targeting oncogenic KRAS mutations in drug-resistant ER+ breast cancer.

Ariella Hanker: AACR26 Is "Still" the Year of RAS Inhibitors

Other articles about breast cancer on OncoDaily.

Breast Cancer cancer David Kerr OncoDaily Oncology Priya Hibshman RAS inhibitors